Eli Lilly (LLY): The Biggest Winner in the GLP-1 Boom?

Dominating the weight-loss revolution with Mounjaro and Zepbound — but is the stock still a buy after its meteoric run?

Eli Lilly has emerged as one of the biggest beneficiaries of the surging demand for GLP-1 weight-loss and diabetes treatments. Its blockbuster drugs, Mounjaro (tirzepatide) and Zepbound, have fueled explosive revenue growth, propelling Lilly’s market cap past $700 billion and cementing its status as a leader in the next era of obesity and metabolic disorder treatments.

Beyond GLP-1 drugs, Lilly boasts a robust pipeline spanning Alzheimer’s, oncology, and autoimmune diseases, positioning it for sustained long-term growth. But the stock’s meteoric rise has sparked debate: is the GLP-1 boom fully priced in, or is there still more room to run?

Let’s take a closer look at what’s driving LLY’s success, its growth outlook, and the investment risks to consider.